Coloplast has increased investment in company behind vapor therapy
![Photo: Coloplast / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13420020.ece/ALTERNATES/schema-16_9/doc7i7x9yk4b141rk0n24.jpg)
Coloplast's faith in a potential vapor ablation treatment for prostate cancer has grown stronger, having participated in a series B equity financing round of the US-based medtech company behind the treatment, the Danish company reports in its year-end report from 2020/2021.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Coloplast expects organic growth of 7 percent next year
For subscribers
Coloplast could win big on Polish reimbursement changes
For subscribers